Nonalcoholic Steatohepatitis – Epidemiology – Asia-Pacific

DRG Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of NASH for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's NASH forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with NASH?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NASH over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following NASH subpopulations:

  • Advanced fibrosis status
  • Obesity status

Note: coverage may vary by country.

Table of contents

  • Nonalcoholic Steatohepatitis - Epidemiology - Asia-Pacific
    • Introduction
      • Key Findings
        • Key Updates
      • Total Prevalence of NASH per 1,000 Among People of All Ages in 2021 and 2031
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of NASH Over the Next Ten Years
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases
      • Prevalent Cases with Obesity
      • Total prevalent Cases of NASH by Fibrosis Stage
      • Diagnosed Prevalent Cases of NASH
      • Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
      • Drug-Treated Cases of NASH
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of NASH
        • Studies Excluded from the Analysis of NASH
      • Risk/Protective Factors
        • Risk/Protective Factors for NASH
      • Bibliography
      • Abbreviations
      • Glossary

Login to access report